Beacon Pointe Advisors’s CorMedix CRMD Stock Holding History

Beacon Pointe Advisors’s Portfolio CRMD Stock Details CRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$188K	Hold	24,000	–	–	﹤0.01%	1818
2026 Q1	$163K	Buy	+24,000	New	+$177K	﹤0.01%	1754
2025 Q3	–	Sell	-24,000	Closed	-$296K	–	1409
2025 Q2	$296K	Hold	24,000	–	–	﹤0.01%	1057
2025 Q1	$148K	Hold	24,000	–	–	﹤0.01%	1172
2024 Q4	$194K	Hold	24,000	–	–	﹤0.01%	1148
2024 Q3	$194K	Hold	24,000	–	–	﹤0.01%	1163
2024 Q2	$104K	Hold	24,000	–	–	﹤0.01%	1227
2024 Q1	$102K	Hold	24,000	–	–	﹤0.01%	1305
2023 Q4	$90.2K	Buy	+24,000	New	+$82.6K	﹤0.01%	1280
2023 Q1	–	Sell	-11,000	Closed	-$46.4K	–	1157
2022 Q4	$46.4K	Hold	11,000	–	–	﹤0.01%	1041
2022 Q3	$31K	Hold	11,000	–	–	﹤0.01%	985
2022 Q2	$44K	Hold	11,000	–	–	﹤0.01%	1024
2022 Q1	$60K	Buy	+11,000	New	+$50.4K	﹤0.01%	1170
2021 Q4	–	Sell	-12,000	Closed	-$56K	–	944
2021 Q3	$56K	Buy	+12,000	New	+$69.9K	﹤0.01%	886

Other funds holding CRMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

OAM

Oberweis Asset Management Lisle, Illinois $4.84B AUM 160.95% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Beacon Pointe Advisors's CRMD Position: Q2 2026 in Review

Beacon Pointe Advisors held its CorMedix (CRMD) position steady in Q2 2026 at 24,000 shares worth $188K. The position accounts for ﹤0.01% of the portfolio, ranked #1818.

Beacon Pointe Advisors first reported a position in CRMD in Q3 2021 and has held it in 14 quarters since. The position peaked at $296K in Q2 2025. 194 funds tracked by Wall St. Rank hold CRMD as of Q2 2026.

Beacon Pointe Advisors held 24,000 shares of CorMedix worth $188K as of Q2 2026.
Beacon Pointe Advisors left its CorMedix share count unchanged in Q2 2026.
CorMedix made up ﹤0.01% of Beacon Pointe Advisors's portfolio in Q2 2026, its #1818 holding.
Beacon Pointe Advisors first reported a position in CorMedix in Q3 2021 and has held it in 14 quarters since.
Beacon Pointe Advisors's CorMedix position peaked at $296K in Q2 2025.
194 funds tracked by Wall St. Rank held CorMedix as of Q2 2026.

Based on Beacon Pointe Advisors's 13F filing for Q2 2026, filed 18 Aug 2026.